Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Customer.Support@LSBio.com - To submit questions about existing orders, pricing, availability,
bulk quotes, proforma invoice requests, or other billing issues.
Technical.Support@LSBio.com - To request technical information requests about an LSBio product
or its application.
Sales@LSBio.com - To request information about fee-for-service contract IHC studies, IHC reports, distribution
agreements, or general business development.
Registration enables users to use special features of this website, such as past
order histories, retained contact details for faster checkout, review submissions, and special promotions.
Registration enables users to use special features of this website, such as past
order histories, retained contact details for faster checkout, review submissions, and special promotions.
Wish List
View Cart
Anti-CDKN3 / KAP Antibody (aa33-59, PE) LS-C207143
CDKN3 encodes a dual specificity protein phosphatase which has been identified as a cyclin-dependent kinase inhibitor and has been shown to interact with, and dephosphorylate human CDK2 kinase. CDKN3 has also been shown to associate with human CDK3 and CDC2. The protein has been reported to remove phosphate from tyrosine residues in model substrates in vitro; however, a mutant protein that bears a lesion in the putative active site cysteine has been shown to lose catalytic activity.